梅州去医院检查妇科流程梅州怀孕微创打胎手术何时做好,梅州怎么医治轻度宫颈炎,梅州做无痛人流晚什么时候,梅州妇产医院医院能做打胎吗,梅州霉菌性宫颈炎怎么办,梅州怀孕3个月人流要多少钱,梅州少女流产医院

BEIJING, March 3 (Xinhuanet) -- A new study suggested that regular use of painkiller ibuprofen may cut the risk of developing Parkinson's disease, according to Reuters reports.The research findings were published in the online edition of the journal Neurology on Wednesday and later will appear in the print edition on March 8.The study, which followed more than 136,000 U.S. men and women for six years, showed that people who took ibuprofen at least twice a week were 38 percent less likely to develop Parkinson's, a brain disorder that causes tremors and movement problems, compared to those who didn't take the pain reliever so often.Ibuprofen is sold in the U.S. as a non-steroidal anti-inflammatory drug (NSAID). But the study didn't prove that other NSAIDS, like aspirin or naproxen, could also cut the Parkinson's risk."Our study suggests ibuprofen could be a potential neuroprotective agent against Parkinson's," says lead researcher Dr. Xiang Gao from Harvard Medical School, "Protective effects are seen after taking ibuprofen two or more times a week. That's so-called regular use."However, he also warned that no proof has been found that ibuprofen itself can help ward off Parkinson's, and said that it's too early to recommend people to start taking ibuprofen to protect against the disorder.Gao said, "We just see an association, not some causal relationship."Besides, regular ibuprofen use has risks, like stomach bleeding and kidney damage.

BEIJING, May 4 (Xinhuanet) -- No formalin has been found in the milk powder imported from S. Korea into China due to different milk sources, the general agency of South Korea's Maeil Dairies said Tuesday.The declaration came after Maeil Dairies, South Korea's third-largest dairy company, was found to have produced milk from cows given feed tainted with formalin.The agency said that the milk used in the dairy products exported to China comes from New Zealand, Europe and other places outside South Korea, so Chinese consumers should have nothing to worry about.Formalin, a liquid form of formaldehyde gas, was largely used in the past as a disinfectant, pesticide and bactericide for preservation of biological specimens.Its use has dwindled over the years due to health concerns.After the incident, South Korea has decided to conduct emergency inspections on milk sold in the market by four major dairy companies, to check the presence of formalin.

WASHINGTON, Jan. 19 (Xinhua) -- China and the United States have agreed to further boost their bilateral relationship toward a cooperative partnership for the benefit of the whole world, President Hu Jintao said Wednesday.The visiting Chinese leader presented the course forward at a joint press conference at the White House with his U.S. counterpart Barack Obama following their eighth meeting in two years.During the talks, conducted in "a candid, pragmatic and constructive atmosphere," the two sides reached "important agreement on China-U.S. relations and major international and regional issues of shared interests," according to the Chinese president.Chinese President Hu Jintao (2nd L) holds a bilateral meeting with U.S. President Barack Obama (2nd R) at the White House in Washington, the United States, Jan. 19, 2011. "We both agree to further push forward the positive, cooperative and comprehensive China-U.S. relationship," Hu said, adding that both sides also pledged to forge "a China-U.S. cooperative partnership based on mutual respect and mutual benefit" for the benefit of the two countries and beyond.Meanwhile, the two sides "should firmly adhere to the right direction," respecting each other's core interests and handling their relations with a long-term perspective, which will enable both countries to make greater contributions to world peace and development, he said.Citing the growing number of global challenges, the Chinese president stressed that Beijing and Washington "share expanding common interests and shoulder increasing common responsibilities."Accordingly, he added, the two sides have agreed to strengthen exchanges and cooperation in economy, trade, environment, education, science and technology, non-proliferation and counter-terrorism among many other fields.During Hu's ongoing state visit, the two countries signed a number of cooperation agreements. "These will inject fresh momentum into our bilateral cooperation and create a great many job opportunities for our two countries," Hu said.He added that he and Obama also discussed some disagreements in the economic and trade area, with both sides pledging "to continue to appropriately resolve these according to the principle of mutual respect and consultation on an equal footing."Commenting on the relations between the countries's armed forces, Hu said, "We believe expansion of military exchanges and cooperation will be conducive to deepening mutual trust between our two countries."On the situation on the Korean Peninsula, he said that both countries agreed to work together with relevant parties to maintain peace and stability on the peninsula, promote denuclearization of the peninsula and achieve lasting peace and security in Northeast Asia.The Chinese leader reaffirmed China's firm commitment to the path of peaceful development and a win-win strategy of opening up, and appreciated Obama's commitment to a positive and constructive China policy."China is a friend and partner of all countries, and China's development is an opportunity for the world," he said.

BEIJING, Apirl 1 (Xinhuanet) -- An Ariane rocket launch of two communications satellites was aborted Wednesday after a technical hitch at the scheduled moment of liftoff in French Guiana on Wednesday.According to Arianespace, the Ariane 5 rocket's Vulcain main engine ignited as scheduled at 5:45 pm EDT (21:45 GMT), but the checkout process during ignition detected an unspecified anomaly, shutting down the engine before the two solid-rocket boosters ignited.The 165-foot (50-meter) tall Ariane 5 rocket's main engine's checkout process "was not completed successfully, preventing the boosters' ignition and thereby aborting the mission," Arianespace officials said. "The Ariane 5 and its two payloads remain in a safe mode on the launch pad."The Ariane 5 rocket uses a Vulcain 2 first stage engine assisted by two solid rocket boosters to launch satellite payloads into orbit. The Vulcain 2 engine is fueled by cryogenic liquid hydrogen and liquid oxygen and is designed to burn for about 600 seconds to boost payloads into space.Jean-Yves Le Gall, Arianespace president, said it would return the rocket to the final assembly building to prepare it for another launch attempt while investigating the cause of the problem. No new launch date was immediately announced.The Ariane 5 was to launch the Yahsat Y1A and Intelsat New Dawn communications satellites.

WASHINGTON, May 20 (Xinhua) -- The U.S. Food and Drug Administration (FDA) on Friday approved Sutent to treat patients with progressive neuroendocrine cancerous tumors located in the pancreas that cannot be removed by surgery or that have spread to other parts of the body.Neuroendocrine tumors found in the pancreas are slow-growing and rare. It is estimated that there are fewer than 1,000 new cases in the United States each year.This is the second new approval by the FDA to treat patients with this disease. On May 5, the agency approved Afinitor."FDA believes it is important to provide cancer patients with as many treatment options as possible," said Richard Pazdur, director of the Office of Oncology Drug Products in the FDA's Center for Drug Evaluation and Research. "The agency is committed to working with companies to bring innovative new therapies to the market and encourages companies to continue exploring additional uses for approved products."The safety and effectiveness of Sutent was established in a single study of 171 patients with metastatic (late-stage) or locally advanced (disease that could not be removed with surgery) disease who received Sutent or a placebo (sugar pill). The study was designed to measure the length of time a patient lived before their disease spread or worsened (progression-free survival).Results from the study demonstrate that Sutent provided benefit to patients by prolonging the median length of time they lived without the cancer spreading or worsening to 10.2 months compared to 5.4 months for patients who received placebo.In patients treated with Sutent for neuroendocrine pancreatic tumors, the most commonly reported side effects included diarrhea, nausea, vomiting, fatigue, anorexia, high blood pressure, energy loss, stomach pain, changes in hair color, inflammation of the mouth, and a decrease in infection-fighting white blood cells.Sutent is marketed by New York City-based Pfizer.